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Actin-binding marine macrolides exhibit significant structural and functional diversity. In this issue, Perrins
et al. demonstrate that a long stereochemically conserved aliphatic side chain, known as the ‘‘tail’’, found
in many of these compounds is the functional determinant of cytotoxicity (Perrins et al., 2008).The sources of cytotoxic marine natural
products are both phylogenetically and
geographically diverse, and their mole-
cular structures are often exquisitely
adapted to specific biological functions
through eons of evolutionary refinement
of their chemical space. Through this pro-
cess, nature has provided ‘‘prevalidated’’
chemical scaffolds with vast pharmaco-
logical potential.
Actin is the target of a conspicuously
large number of natural products that
bind actin filaments and stop or acceler-
ate their growth, chop them up, or inhibit
their formation altogether (Figure 1). The
structural features of these compounds
can vary significantly and, until a short
time ago, the details of their molecular in-
teractions with actin, aswell as their mode
of action, were enigmatic. However, re-
cent studies are beginning to shed light
on unifying elements in certain classes ofthese compounds that determine their
function (Allingham et al., 2006). These
studies are also providing insight into
how analogs of these compounds can
be designed to retain the potency of the
natural form, yet be tailored for specific
uses in clinical or laboratory settings.
Perrins et al. now provide significant mo-
mentum to rational actin-targeted drug
design, reporting that only a portion of
a natural product is required for activity
when this component is elaborated with
a simple aromatic group in place of the
missing structural features of the natural
form.
Actin is a globular protein that can poly-
merize into helical filaments (Figure 2),
which form a three-dimensional network
inside eukaryotic cells. Dynamic remodel-
ing of actin filaments in the cytosol drives
shape changes, cell locomotion, and che-
motactic migration that are vital to tissueChemistry & Biology 15, March 200development, wound healing, neuron mi-
gration, immune responses, and mainte-
nance of homeostasis. However, this ac-
tivity of actin also facilitates division and
migration of tumor cells, microbial infec-
tion, and other disease states when not
properly regulated. Therefore, actin is rec-
ognized as a strategic target for the devel-
opment of new anticancer drugs and
other therapeutic agents.
There are at least six different natural
product binding sites on actin, however,
the majority of compounds appear to
bind the barbed end of actin. This could
indicate that this is the best place to target
actin-binding drugs to produce an effect
and that natural products that target
this site may provide an excellent source
of inspiration for drug design. Recently,
a number of cytotoxic macrolides, such
as reidispongiolides, sphinxolides, aplyr-
onines, and ulapualides that bind to theFigure 1. Barbed End-Targeting Macrolides
The chemical structures of representative members of known or inferred actin barbed end-targeting natural products are shown.8 ª2008 Elsevier Ltd All rights reserved 205
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Reidispongiolide A and a Synthetic Analog
The structure of reidispongiolide A (purple spheres) bound to actin (PDB code: 2ASM) is shown on the left
superimposed onto a modified F-actin model (PDB code: 1O1E) depicting the hypothetical mechanism of
filament severing and capping (left panel). Reidispongiolide A (purple ball-and-sticks) and manually
docked reidispongiolide analog 5 (green ball-and-sticks) from Perrins et al. (2008) are shown on the top
right superimposed onto a surface representation of actin (PDB code: 2ASM). The chemical structure
of reidispongiolide analog 5 is shown below.barbed end of actin with nanomolar affin-
ity and disrupt actin filament dynamics
have attracted significant attention as
novel anticancer drug leads. These com-
pounds are lethal to tumor cells, including
those possessing multiple drug resis-
tance, and several of them have been in-
cluded in the National Cancer Institute’s
Molecular Targets Development Program
(Braet et al., 2008; Fenteany and Zhu,
2003; Spector et al., 1999). So far, how-
ever, no actin-binding drugs have broken
beyond the preclinical testing stage due
to their extreme cytotoxicity and impar-
tiality to normal and diseased cells. One
route that holds promise in overcoming
this obstacle is to design synthetic com-
pounds that integrate the key elements
producing the actin-targeting functions
of compounds tailored by nature with
cell-specific targeting elements. Fortu-
nately, the complex structural features of
the above macrolides attract synthesis206 Chemistry & Biology 15, March 2008 ª2chemists like Ian Paterson, who accom-
plished the total syntheses of several ac-
tin-binding macrolides (Paterson et al.,
2007). Their achievements provide excel-
lent opportunities to dissect the structural
requirements for bioactivity of natural
products by utilizing synthetic intermedi-
ates.
In order to define the key actin-target-
ing elements, a number of groups also
have begun correlating the effects of dif-
ferent macrolide congeners, artificial ana-
logs, and toxin fragments on purified actin
filament dynamics and cell-based cyto-
toxicity assays (Allingham et al., 2005;
Perrins et al., 2008; Suenaga et al.,
1997; Vincent et al., 2007). X-ray crystal
structures of several of these compounds
bound to actin have aided enormously to
this endeavor by revealing common ac-
tin-toxin binding interfaces and providing
a molecular explanation for their mode of
filament-destabilization (Allingham et al.,008 Elsevier Ltd All rights reserved2005; Hirata et al., 2006; Klenchin et al.,
2003). Collectively, these studies have
uncovered unifying structure-cytotoxicity
relationships for these macrolides.
Barbed end-binding macrolides typi-
cally possess a structurally variable hy-
drophobic macrocycle (the ‘‘ring’’) and
a long and flexible aliphatic side chain
(the ‘‘tail’’) with conserved stereochemis-
try that terminateswith a highly conserved
N-methyl-vinylformamide (MVF) moiety
(Figure 1). The tail section intercalates
into the narrow hydrophobic cleft splitting
subdomains 1 and 3 at the barbed end of
actin and forms critical stabilizing interac-
tions via the MVF moiety (Allingham et al.,
2005; Klenchin et al., 2003; Figure 2).
Also, several conserved side groups along
the length of the tail complement the
irregular surface of the actin cleft to help
impose the tail’s extended conformation.
Altogether, a tight interaction is created
with a surface on actin that is involved in
important actin-actin contacts formed
during actin polymerization (Klenchin
et al., 2003; Tanaka et al., 2003; Figure 2).
While the ring of barbed end-binding
macrolides also makes important interac-
tions with actin at a separate surface that
is exposed in both the polymerized and
nonpolymerized state, there is significant
variability in how the ring of different
toxins engage this surface that appears
to correlate with the structural variability
of this component. These observations
provided the first indication that the
affinity of these compounds for actin and
their cytotoxicity are determined by a
subset of key structural features, and
that most of their functionality resided in
the tail region.
Perrins et al. (2008) now provide further
clarification of the importance of the tail
region by characterizing the structure-
activity relationships of synthetic analogs
of the tail portion of reidispongiolide. Their
observation that analogs consisting pri-
marily of the tail section alone retained ac-
tin-binding, polymerization inhibition, and
filament severing activities demonstrates
that the tail is the key determinant of actin
filament dynamics inhibition, and thus
confirms the importance of maintaining
the tail in future actin-targeting drug de-
sign efforts. It also provides an optimistic
outlook for the development of simplified
natural product mimics whose molecular
masses fulfill a parameter of Lipinski’s
Rule of Five (Lipinski et al., 2001).
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PreviewsGiven that the tail comprises only
40% of the total surface area of the
toxins and the fact this feature is highly
conserved across different cytotoxin fam-
ilies, the work by Perrins et al. raises
important questions about whymarine or-
ganisms go to the trouble to produce
complex macrocycles. Their observation
that the functionality of the tail segment
was significantly enhanced with the addi-
tion of an aromatic group (a para-methox-
yphenyl acetal protecting group), which is
in actuality an artifact of the chemical syn-
thesis, indicates that the macrocycle is
not entirely superfluous, but can be mod-
ified or substituted with alternative hydro-
phobicmoieties to help stabilize the actin-
drug complex. Cursory docking of the
most bioactive analog onto the structural
coordinates of actin in its reidispongiolide
A-bound conformation lends support to
this hypothesis (Figure 2). The aromatic
group could, in part, reconstitute impor-
tant hydrophobic interactions with the
shallow hydrophobic patch on actin that
is contacted by analogous regions of
many diverse barbed end-binding macro-
lides. Notably, this portion of the ring was
previously been described as a likely
component of the pharmacophore of
these compounds (Allingham et al.,
2006; Melville et al., 2007). ElaborationHow to Identify a P
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The inhibition of chitinases by argifin
of kinetic and crystallographicmetho
ing of structure-activity relationship
In this issue of Chemistry & Biology, van
Aalten and colleagues describe the identi-
fication of dimethylguanylurea as a phar-
macophor for family 18 chitinases (Ander-
sen et al., 2008). Dimethylguanylurea
forms the terminus of the major side chain
of argifin, a modified cyclopentapeptide
which is a potent chitinase inhibitor. Inof the tail segment with other hydrophobic
moieties in place of this portion of the ring
could serve a dual role of stabilizing the
interaction of the tail with actin, likely by
reducing the entropy of binding, and
providing a scaffold for appending cell-
specific targeting ligands or optical
probes.
In addition to the direct therapeutic ap-
plications, the work of investigators like
Perrins et al. could also stimulate novel
areas of interest in the development of ac-
tin-binding ligands as diagnostic or prog-
nostic tools based on alterations of the
cytoskeletal properties of tumor cells.
On a more general note, such work may
have important implications on the design
of drugs that are intended to disrupt pro-
tein-protein interactions based on the
filament-disrupting mechanism of these
compounds.
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